The results showed a significant increase in tumor-infiltrating T lymphocytes in patients with clear cell carcinoma in the combination therapy group compared to anti-CTLA-4 monotherapy, while no similar phenomenon was observed in patients with non-clear cell carcinoma. Here, CTLA4 is linked to neoplasm.